Literature DB >> 15694367

Hypertrophic effects of urocortin homologous peptides are mediated via activation of the Akt pathway.

Anastasios Chanalaris1, Kevin M Lawrence, Paul A Townsend, Sean Davidson, Yalda Jamshidi, Yalda Jashmidi, Anastasis Stephanou, Richard D Knight, Sheau Y Hsu, Aaron J W Hsueh, David S Latchman.   

Abstract

The UCN homologues SCP and SRP bind specifically to the CRFR2 receptor, whereas UCN binds to both CRFR1 and CRFR2. We have previously demonstrated that all three peptides are cardioprotective, and both the Akt and MAPK p42/44 pathways are essential for this effect. Here we tested the hypertrophic effects of these peptides. We examined the effects of the peptides on cell area, protein synthesis, and induction of the natriuretic peptides ANP and BNP. All three peptides were able to increase all the markers of hypertrophy examined, with SCP being the most potent of the three, followed by UCN and SRP last. In addition, we provide a mechanism of action for the three peptides and show that Akt phosphorylation is important for their hypertrophic action, whereas MAPK p42/44 is not involved in this effect.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15694367     DOI: 10.1016/j.bbrc.2005.01.001

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

1.  NFAT transcription factor regulation by urocortin II in cardiac myocytes and heart failure.

Authors:  Stefanie Walther; Sawsan Awad; Vassyl A Lonchyna; Lothar A Blatter
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-01-17       Impact factor: 4.733

2.  Urocortin-induced cardiomyocytes hypertrophy is associated with regulation of the GSK-3β pathway.

Authors:  Damien Gruson; Audrey Ginion; Noémie Decroly; Pascale Lause; Jean-Louis Vanoverschelde; Jean-Marie Ketelslegers; Luc Bertrand; Jean-Paul Thissen
Journal:  Heart Vessels       Date:  2011-04-20       Impact factor: 2.037

Review 3.  Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: ancient CRF paralogs.

Authors:  Eva M Fekete; Eric P Zorrilla
Journal:  Front Neuroendocrinol       Date:  2006-11-02       Impact factor: 8.606

4.  Activation of phosphatidylinositol 3-kinase/protein kinase B by corticotropin-releasing factor in human monocytes.

Authors:  Christina Chandras; Yassemi Koutmani; Efi Kokkotou; Charalabos Pothoulakis; Katia P Karalis
Journal:  Endocrinology       Date:  2009-07-23       Impact factor: 4.736

5.  Comparative pharmacokinetics and pharmacodynamics of urocortins 1, 2 and 3 in healthy sheep.

Authors:  K Patel; M T Rademaker; C M J Kirkpatrick; C J Charles; S Fisher; T G Yandle; A M Richards
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

6.  A closer look at the role of urotensin II in the metabolic syndrome.

Authors:  Pierre-Olivier Barrette; Adel Giaid Schwertani
Journal:  Front Endocrinol (Lausanne)       Date:  2012-12-28       Impact factor: 5.555

7.  New targets of urocortin-mediated cardioprotection.

Authors:  Seán P Barry; Kevin M Lawrence; James McCormick; Surinder M Soond; Mike Hubank; Simon Eaton; Ahila Sivarajah; Tiziano M Scarabelli; Richard A Knight; Christoph Thiemermann; David S Latchman; Paul A Townsend; Anastasis Stephanou
Journal:  J Mol Endocrinol       Date:  2010-05-25       Impact factor: 5.098

8.  Urocortin 3 activates AMPK and AKT pathways and enhances glucose disposal in rat skeletal muscle.

Authors:  Manon M Roustit; Joan M Vaughan; Pauline M Jamieson; Mark E Cleasby
Journal:  J Endocrinol       Date:  2014-08-13       Impact factor: 4.286

9.  Urocortin Treatment Improves Acute Hemodynamic Instability and Reduces Myocardial Damage in Post-Cardiac Arrest Myocardial Dysfunction.

Authors:  Chien-Hua Huang; Chih-Hung Wang; Min-Shan Tsai; Nai-Tan Hsu; Chih-Yen Chiang; Tzung-Dau Wang; Wei-Tien Chang; Huei-Wen Chen; Wen-Jone Chen
Journal:  PLoS One       Date:  2016-11-10       Impact factor: 3.240

10.  Urocortin-2 Prevents Dysregulation of Ca2+ Homeostasis and Improves Early Cardiac Remodeling After Ischemia and Reperfusion.

Authors:  Alejandro Domínguez-Rodríguez; Isabel Mayoral-Gonzalez; Javier Avila-Medina; Eva S de Rojas-de Pedro; Eva Calderón-Sánchez; Ignacio Díaz; Abdelkrim Hmadcha; Antonio Castellano; Juan A Rosado; Jean-Pierre Benitah; Ana M Gomez; Antonio Ordoñez; Tarik Smani
Journal:  Front Physiol       Date:  2018-07-03       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.